[1]. Surgeon General’s Call to Action to Prevent Skin Cancer. MMWR Morbidity and Mortality Weekly Report, 2014. 63(30).
[2]. Kraemer, K H, Sunlight and skin cancer: Another link revealed. Proceedings of the National Academy of Sciences of the United States of America, 1997. 94(1): p. 11-14.
[3]. Society, A C, Cancer Facts & Figures 2021. Atlanta: American Cancer Society, 2021.
[4]. Rogers, H W, M A Weinstock, S R Feldman, et al., Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012. Jama Dermatology, 2015. 151(10): p. 1081-1086.
[5]. Mansouri, B and C D Housewright, The Treatment of Actinic Keratoses-The Rule Rather Than the Exception. Jama Dermatology, 2017. 153(11): p. 1200-1200.
[6]. Guy, G P, Jr., S R Machlin, D U Ekwueme, et al., Prevalence and Costs of Skin Cancer Treatment in the US, 2002-2006 and 2007-2011. American Journal of Preventive Medicine, 2015. 48(2): p. 183-187.
[7]. Barzel, U S, THE MERCK MANUAL OF DIAGNOSIS AND THERAPY - BERKOW,R. Journal of the American Geriatrics Society, 1982. 30(11): p. 727-728.
[8]. Cummins, D L, J M Cummins, H Pantle, et al., Cutaneous malignant melanoma. Mayo Clinic Proceedings, 2006. 81(4): p. 500-507.
[9]. Feuerstein, I and A C Geller, Skin cancer education in transplant recipients. Progress in Transplantation, 2008. 18(4): p. 232-241.
[10]. McCormack, C J, J W Kelly and A P Dorevitch, Differences in age and body site distribution of the histological subtypes of basal cell carcinoma - A possible indicator of differing causes. Archives of Dermatology, 1997. 133(5): p. 593-596.
[11]. Lee, D A and S J Miller, Nonmelanoma skin cancer. Facial plastic surgery clinics of North America, 2009. 17(3): p. 309-24.
[12]. Kallini, J R, N Hamed and A Khachemoune, Squamous cell carcinoma of the skin: epidemiology, classification, management, and novel trends. International Journal of Dermatology, 2015. 54(2): p. 130-140.
[13]. FOUNDATION, S C, Our New Approach to a Challenging Skin Cancer Statistic. 2021.
[14]. Rundel, R D and D S Nachtwey, SKIN CANCER AND ULTRAVIOLET-RADIATION. Photochemistry and Photobiology, 1978. 28(3): p. 345-356.
[15]. Gailani, M R, D J Leffell, A Ziegler, et al., Relationship between sunlight exposure and a key genetic alteration in basal cell carcinoma. Journal of the National Cancer Institute, 1996. 88(6): p. 349-354.
[16]. Brenner, M and V J Hearing, The protective role of melanin against UV damage in human skin. Photochemistry and Photobiology, 2008. 84(3): p. 539-549.
[17]. Madan, V, J T Lear and R-M Szeimies, Non-melanoma skin cancer. Lancet, 2010. 375(9715): p. 673-685.
[18]. Watson, M, D M Holman and M Maguire-Eisen, ULTRAVIOLET RADIATION EXPOSURE AND ITS IMPACT ON SKIN CANCER RISK. Seminars in Oncology Nursing, 2016. 32(3): p. 241-254.
[19]. Rho, O, D J Kim, K Kiguchi, et al., Growth Factor Signaling Pathways as Targets for Prevention of Epithelial Carcinogenesis. Molecular Carcinogenesis, 2011. 50(4): p. 264-279.
[20]. Yarden, Y and M X Sliwkowski, Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology, 2001. 2(2): p. 127-137.
[21]. Meyer-Schwesinger, C, The ubiquitin-proteasome system in kidney physiology and disease. Nature Reviews Nephrology, 2019. 15(7): p. 393-411.
[22]. Lynn, B, L James, D L R, et al., Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nature reviews. Drug discovery, 2011. 10(1).
[23]. Michael, R, Ubiquitylation at the crossroads of development and disease. Nature reviews. Molecular cell biology, 2018. 19(1).
[24]. Hodson, C, A Purkiss, Jennifer A Miles, et al., Structure of the Human FANCL RING-Ube2T Complex Reveals Determinants of Cognate E3-E2 Selection. Structure, 2014. 22(2).
[25]. J, M, K K B and C C M, The ubiquitin-proteasome pathway and proteasome inhibitors. Medicinal research reviews, 2001. 21(4).
[26]. J, P P, Y H, S O, et al., The C2 domain of the ubiquitin protein ligase Nedd4 mediates Ca2+-dependent plasma membrane localization. The Journal of biological chemistry, 1997. 272(51).
[27]. E, B C and W Cynthia, New insights into ubiquitin E3 ligase mechanism. Nature structural & molecular biology, 2014. 21(4).
[28]. Morreale, F E and H Walden, Types of Ubiquitin Ligases. Cell, 2016. 165(1).
[29]. Zheng, N and N Shabek, Ubiquitin Ligases: Structure, Function, and Regulation. Annual Review of Biochemistry, 2017. 86(1).
[30]. Deshaies, R J and C A P Joazeiro, RING Domain E3 Ubiquitin Ligases. Annual Review of Biochemistry, 2009. 78(1).
[31]. Scheffner, M and S Kumar, Mammalian HECT ubiquitin-protein ligases: Biological and pathophysiological aspects. BBA - Molecular Cell Research, 2014. 1843(1).
[32]. Jasper, S and D Ben, Regulating the human HECT E3 ligases. Cellular and molecular life sciences : CMLS, 2018. 75(17).
[33]. Daniela, R and K Sharad, Physiological functions of the HECT family of ubiquitin ligases. Nature reviews. Molecular cell biology, 2009. 10(6).
[34]. J, I R, G Gerald and P Tony, The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture. Oncogene, 2004. 23(11).
[35]. Zou, X, G Levy-Cohen and M Blank, Molecular functions of NEDD4 E3 ubiquitin ligases in cancer. BBA - Reviews on Cancer, 2015. 1856(1).
[36]. S, K, T Y and N M, Identification of a set of genes with developmentally down-regulated expression in the mouse brain. Biochemical and biophysical research communications, 1992. 185(3).
[37]. Kumar, S, K F Harvey, M Kinoshita, et al., cDNA Cloning, Expression Analysis, and Mapping of the Mouse Nedd4 Gene. Genomics, 1997. 44(1).
[38]. Xian, Z, L Binkui, R A Hossein, et al., H3 ubiquitination by NEDD4 regulates H3 acetylation and tumorigenesis. Nature communications, 2017. 8(1).
[39]. Staub, O, S Dho, P C Henry, et al., WW domains of Nedd4 bind to the proline-rich PY motifs in the epithelial Na+ channel deleted in Liddle's syndrome. Embo Journal, 1996. 15(10): p. 2371-2380.
[40]. Ingham, R J, K Colwill, C Howard, et al., WW domains provide a platform for the assembly of multiprotein networks. Molecular and Cellular Biology, 2005. 25(16): p. 7092-7106.
[41]. Hatstat, A K, H D Ahrendt, M W Foster, et al., Characterization of Small-Molecule-Induced Changes in Parkinson's-Related Trafficking via the Nedd4 Ubiquitin Signaling Cascade. Cell Chemical Biology, 2021. 28(1): p. 14-+.
[42]. Wang, Z-W, X Hu, M Ye, et al., NEDD4 E3 ligase: Functions and mechanism in human cancer. Seminars in Cancer Biology, 2020. 67: p. 92-101.
[43]. Daly, R J, The Grb7 family of signalling proteins. Cellular Signalling, 1998. 10(9): p. 613-618.
[44]. Morrione, A, P Plant, B Valentinis, et al., mGrb10 interacts with Nedd4. Journal of Biological Chemistry, 1999. 274(34): p. 24094-24099.
[45]. Vecchione, A, A Marchese, P Henry, et al., The Grb10/Nedd4 complex regulates ligand-induced ubiquitination and stability of the insulin-like growth factor I receptor. Molecular and Cellular Biology, 2003. 23(9): p. 3363-3372.
[46]. Monami, G, V Emiliozzi and A Morrione, Grb10/Nedd4-mediated multiubiquitination of the insulin-like growth factor receptor regulates receptor internalization. Journal of Cellular Physiology, 2008. 216(2): p. 426-437.
[47]. Pollak, M, Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews Cancer, 2008. 8(12): p. 915-928.
[48]. De Meyts, P, Insulin/receptor binding: The last piece of the puzzle? Bioessays, 2015. 37(4): p. 389-397.
[49]. Adams, T E, V C Epa, T P J Garrett, et al., Structure and function of the type 1 insulin-like growth factor receptor. Cellular and Molecular Life Sciences, 2000. 57(7): p. 1050-1093.
[50]. Butler, A A, S Yakar, I H Gewolb, et al., Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology. Comparative Biochemistry and Physiology B-Biochemistry & Molecular Biology, 1998. 121(1): p. 19-26.
[51]. Bach, L A, IGF-binding proteins. Journal of Molecular Endocrinology, 2018. 61(1): p. T11-T28.
[52]. Forbes, B E, P McCarthy and R S Norton, Insulin-like growth factor binding proteins: a structural perspective. Frontiers in endocrinology, 2012. 3: p. 38-38.
[53]. Baxter, R C, IGF binding proteins in cancer: mechanistic and clinical insights. Nature Reviews Cancer, 2014. 14(5): p. 329-341.
[54]. Taguchi, A and M F White, Insulin-like signaling, nutrient homeostasis, and life span. Annual Review of Physiology, 2008. 70: p. 191-212.
[55]. Taniguchi, C M, B Emanuelli and C R Kahn, Critical nodes in signalling pathways: insights into insulin action. Nature Reviews Molecular Cell Biology, 2006. 7(2): p. 85-96.
[56]. Romanelli, R J, A P LeBeau, C G Fulmer, et al., Insulin-like growth factor type-I receptor internalization and recycling mediate the sustained phosphorylation of Akt. Journal of Biological Chemistry, 2007. 282(31).
[57]. Nicholson, R I, I R Hutcheson, M E Harper, et al., Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer, in Hormone-Related Tumors: Novel Approaches to Prevention and Treatment, L. Castanetta, et al., Editors. 2002. p. 104-115.
[58]. Thompson, E J, J MacGowan, M R Young, et al., A dominant negative c-jun specifically blocks okadaic acid-induced skin tumor promotion. Cancer Research, 2002. 62(11): p. 3044-3047.
[59]. Sun, Y, X Sun and B Shen, Molecular Imaging of IGF-1R in Cancer. Molecular Imaging, 2017. 16.
[60]. Hakam, A, T J Yeatman, L Lu, et al., Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Human Pathology, 1999. 30(10).
[61]. Buck, E, A Eyzaguirre, M Rosenfeld-Franklin, et al., Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors. Cancer Research, 2008. 68(20): p. 8322-8332.
[62]. Chen, F L, W Xia and N L Spector, Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors. Clinical Cancer Research, 2008. 14(21): p. 6730-6734.
[63]. Cohen, B D, D A Baker, C Soderstrom, et al., Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clinical Cancer Research, 2005. 11(5): p. 2063-2073.
[64]. Garcia-Echeverria, C, M A Pearson, A Marti, et al., In vivo antitumor activity of NVP-AEW541 - A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell, 2004. 5(3): p. 231-239.
[65]. Maloney, E K, J L McLaughlin, N E Dagdigian, et al., An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Research, 2003. 63(16): p. 5073-5083.
[66]. Kasprzak, A, W Kwasniewski, A Adamek, et al., Insulin-like growth factor (IGF) axis in cancerogenesis. Mutation Research-Reviews in Mutation Research, 2017. 772: p. 78-104.
[67]. Kim, S Y, J A Toretsky, D Scher, et al., The Role of IGF-1R in Pediatric Malignancies. Oncologist, 2009. 14(1): p. 83-91.
[68]. Werner, H and I Bruchim, The insulin-like growth factor-I receptor as an oncogene. Archives of physiology and biochemistry, 2009. 115(2): p. 58-71.
[69]. Lann, D and D LeRoith, The Role of Endocrine Insulin-Like Growth Factor-I and Insulin in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2008. 13(4): p. 371-379.
[70]. Fukuda, R, K Hirota, F Fan, et al., Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. Journal of Biological Chemistry, 2002. 277(41): p. 38205-38211.
[71]. Dallas, N A, L Xia, F Fan, et al., Chemoresistant Colorectal Cancer Cells, the Cancer Stem Cell Phenotype, and Increased Sensitivity to Insulin-like Growth Factor-I Receptor Inhibition. Cancer Research, 2009. 69(5): p. 1951-1957.
[72]. Chang, W-W, R-J Lin, J Yu, et al., The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors. Breast Cancer Research, 2013. 15(3).
[73]. Chang, T-S, C-L Chen, Y-C Wu, et al., Inflammation Promotes Expression of Stemness-Related Properties in HBV-Related Hepatocellular Carcinoma (vol 11, e0149897, 2016). Plos One, 2017. 12(1).
[74]. Xu, C, D Xie, S-C Yu, et al., beta-Catenin/POU5F1/SOX2 Transcription Factor Complex Mediates IGF-I Receptor Signaling and Predicts Poor Prognosis in Lung Adenocarcinoma. Cancer Research, 2013. 73(10): p. 3181-3189.
[75]. Hart, L S, N G Dolloff, D T Dicker, et al., Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle, 2011. 10(14): p. 2331-2338.
[76]. Urtasun, N, A Vidal-Pla, S Perez-Torras, et al., Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors. Bmc Cancer, 2015. 15.
[77]. Bowers, L W, E L Rossi, C H O'Flanagan, et al., The role of the insulin/IGF system in cancer: lessons learned from clinical trials and the energy balance-cancer link. Frontiers in Endocrinology, 2015. 6.
[78]. Yoon, S-O, S Shin, F A Karreth, et al., Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition. Molecular Cell, 2017. 67(3): p. 512-+.
[79]. Rudman, S M, M P Philpott, G A Thomas, et al., The role of IGF-I in human skin and its appendages: Morphogen as well as mitogen? Journal of Investigative Dermatology, 1997. 109(6): p. 770-777.
[80]. Tsitsipatis, D, L-O Klotz and H Steinbrenner, Multifaceted functions of the forkhead box transcription factors FoxO1 and FoxO3 in skin. Biochimica Et Biophysica Acta-General Subjects, 2017. 1861(5): p. 1057-1064.
[81]. DiGiovanni, J, D K Bol, E Wilker, et al., Constitutive expression of insulin-like growth factor-1 in epidermal basal cells of transgenic mice leads to spontaneous tumor promotion. Cancer Research, 2000. 60(6): p. 1561-1570.
[82]. Jung, M, S Y Bu, K-H Tak, et al., Anticarcinogenic effect of quercetin by inhibition of insulin-like growth factor (IGF)-1 signaling in mouse skin cancer. Nutrition Research and Practice, 2013. 7(6): p. 439-445.
[83]. Gunduz, O, O Gokoz, G Erkin, et al., Comparison of growth hormone receptor, igf-1r and igfbp-3 between tumoral and non-tumoral areas in non-melanoma skin cancers. Turk patoloji dergisi, 2013. 29(3): p. 185-92.
[84]. Oh, S-T, Y-S Eun, D-S Yoo, et al., Expression of Insulin-like Growth Factor-1 Receptor in Conventional Cutaneous Squamous Cell Carcinoma With Different Histological Grades of Differentiation. American Journal of Dermatopathology, 2014. 36(10): p. 807-811.
[85]. Neudauer, C L and J B McCarthy, Insulin-like growth factor I-stimulated melanoma cell migration requires phosphoinositide 3-kinase but not extracellular-regulated kinase activation. Experimental Cell Research, 2003. 286(1).
[86]. Economou, M A, S Andersson, D Vasilcanu, et al., Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma. Investigative Ophthalmology & Visual Science, 2008. 49(6): p. 2337-2342.
[87]. Wang, J, T Sinnberg, H Niessner, et al., PTEN regulates IGF-1R-mediated therapy resistance in melanoma. Pigment Cell & Melanoma Research, 2015. 28(5): p. 572-589.
[88]. Puzanov, I, C R Lindsay, L Goff, et al., A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2015. 21(4): p. 701-711.
[89]. Mahadevan, D, G R Sutton, R Arteta-Bulos, et al., Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer Chemotherapy and Pharmacology, 2014. 73(3): p. 467-473.
[90]. Macaulay, V M, M R Middleton, A S Protheroe, et al., Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. Annals of Oncology, 2013. 24(3): p. 784-791.
[91]. Kanter-Lewensohn, L, A Dricu, M Wang, et al., Expression of the insulin-like growth factor-1 receptor and its anti-apoptotic effect in malignant melanoma: a potential therapeutic target. Melanoma Research, 1998. 8(5): p. 389-397.
[92]. Vasilcanu, D, W H Weng, A Girnita, et al., The insulin-like growth factor-1 receptor inhibitor PPP produces only very limitedresistance in tumor cells exposed to long-term selection. Oncogene, 2006. 25(22): p. 3186-3195.
[93]. Rudnick, E W, S Thareja and B Cherpelis, Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies. International Journal of Dermatology, 2016. 55(3): p. 249-258.
[94]. Huang, Q and D M E Szebenyi, Structural Basis for the Interaction between the Growth Factor-binding Protein GRB 10 and the E3 Ubiquitin Ligase NEDD4. Journal of Biological Chemistry, 2010. 285(53): p. 42130-42139.
[95]. Yang, S, H Deng, Q Zhang, et al., Amelioration of Diabetic Mouse Nephropathy by Catalpol Correlates with Down-Regulation of Grb10 Expression and Activation of Insulin-Like Growth Factor 1 / Insulin-Like Growth Factor 1 Receptor Signaling. Plos One, 2016. 11(3).
[96]. Dawid, I B, J J Breen and R Toyama, LIM domains: multiple roles as adapters and functional modifiers in protein interactions. Trends in Genetics, 1998. 14(4): p. 156-162.
[97]. Wang-Rodriguez, J, A D Dreilinger, G M Alsharabi, et al., The signaling adapter protein PINCH is up-regulated in the stroma of common cancers, notably at invasive edges. Cancer, 2002. 95(6): p. 1387-1395.
[98]. Zhu, Z, Y Yang, Y Zhang, et al., PINCH expression and its significance in esophageal squamous cell carcinoma. Disease Markers, 2008. 25(2): p. 75-80.
[99]. Wang, M-J, J Ping, Y Li, et al., Prognostic Significance and Molecular Features of Colorectal Mucinous Adenocarcinomas A Strobe-Compliant Study. Medicine, 2015. 94(51).
[100].Fukuda, T, K Chen, X H Shi, et al., PINCH-1 is an obligate partner of integrin-linked kinase (ILK) functioning in cell shape modulation, motility, and survival. Journal of Biological Chemistry, 2003. 278(51): p. 51324-51333.
[101].Guo, L, R Wang, K Zhang, et al., A PINCH-1-Smurf1 signaling axis mediates mechano-regulation of BMPR2 and stem cell differentiation. Journal of Cell Biology, 2019. 218(11): p. 3773-3794.
[102].Li, S H, R Bordoy, F Stanchi, et al., PINCH1 regulates cell-matrix and cell-cell adhesions, cell polarity and cell survival during the peri-implantation stage. Journal of Cell Science, 2005. 118(13): p. 2913-2921.
[103].Karakoese, E, T Geiger, K Flynn, et al., The focal adhesion protein PINCH-1 associates with EPLIN at integrin adhesion sites. Journal of Cell Science, 2015. 128(5): p. 1023-1033.
[104].Ramirez, A, A Page, A Gandarillas, et al., A keratin K5Cre transgenic line appropriate for tissue-specific or generalized Cre-mediated recombination. Genesis, 2004. 39(1): p. 52-57.
[105].Bander, T S, K S Nehal and E H Lee, Cutaneous Squamous Cell Carcinoma Updates in Staging and Management. Dermatologic Clinics, 2019. 37(3): p. 241-+.
[106].Rinat, Y, G K A, L Samuel, et al., Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast cancer research and treatment, 2012. 132(1).
[107].Darido, C, S R Georgy, T Wilanowski, et al., Targeting of the Tumor Suppressor GRHL3 by a miR-21-Dependent Proto-Oncogenic Network Results in PTEN Loss and Tumorigenesis. Cancer Cell, 2011. 20(5): p. 635-648.
[108].Huang, P Y and A Balmain, Modeling Cutaneous Squamous Carcinoma Development in the Mouse. Cold Spring Harbor Perspectives in Medicine, 2014. 4(9).
[109].Boutwell, R K, A K Verma, C L Ashendel, et al., Mouse skin: a useful model system for studying the mechanism of chemical carcinogenesis. Carcinogenesis; a comprehensive survey, 1982. 7: p. 1-12.
[110].Yuspa, S H, Overview of carcinogenesis: past, present and future. Carcinogenesis, 2000. 21(3): p. 341-344.
修改评论